Comparative Pharmacology
Head-to-head clinical analysis: CONSENSI versus RAUVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONSENSI versus RAUVAL.
CONSENSI vs RAUVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Consensi is a fixed-dose combination of amlodipine, a dihydropyridine calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Celecoxib inhibits prostaglandin synthesis via COX-2, reducing inflammation and pain.
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Adults: 0.25 mg/kg intravenously over 1 hour every 2 weeks.
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
None Documented
None Documented
Terminal elimination half-life of 12-15 hours for parent drug and 18-24 hours for active metabolite, allowing once-daily dosing.
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Primarily renal (70-80% as unchanged drug and active metabolite desmethyl-consensi); biliary/fecal: 15-20%.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Category C
Category C
Antihypertensive/NSAID Combination
Antihypertensive